The onset of EGFR resistance can trigger alternative signaling pathways through association with other receptor tyrosine kinases [14, 15] or G-protein coupled receptors (GPCRs) [16] to maintain the tumor phenotype but these precise mechanisms remain only partially understood. The gene discussed is EGFR; the disease is neoplasm.